|
|
A BILL TO BE ENTITLED
|
|
AN ACT
|
|
relating to adding certain substances to the Texas Controlled |
|
Substances Act and regulating kratom and kratom products; |
|
increasing civil penalties; creating criminal offenses; increasing |
|
a criminal penalty. |
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
SECTION 1. Chapter 444, Health and Safety Code, as added by |
|
Chapter 2 (S.B. 497), Acts of the 88th Legislature, Regular |
|
Session, 2023, is redesignated as Chapter 445, Health and Safety |
|
Code, and amended to read as follows: |
|
CHAPTER 445 [444]. MANUFACTURE, DISTRIBUTION, AND SALE OF KRATOM |
|
PRODUCTS |
|
Sec. 445.001 [444.001]. DEFINITIONS. In this chapter: |
|
(1) "Food" has the meaning assigned by Section |
|
431.002. |
|
(2) "Kratom" means any part of the leaf of the plant of |
|
the species Mitragyna speciosa. |
|
(3) "Kratom processor" means a person who: |
|
(A) processes kratom for a kratom product; |
|
(B) manufactures, prepares, or distributes[, or |
|
maintains] kratom products for sale; |
|
(C) [(B)] advertises, represents, or holds |
|
oneself out as a manufacturer or[,] preparer[, or seller] of kratom |
|
products; |
|
(D) [(C)] is responsible for ensuring the purity |
|
and proper labeling of kratom products; or |
|
(E) [(D)] packages or labels kratom products. |
|
(4) "Kratom product" means a food that contains[, |
|
including an extract, capsule, or pill, containing any form of] |
|
kratom. |
|
(5) "Kratom retailer" means a person [kratom |
|
processor] who sells or offers for sale kratom products to |
|
consumers or who advertises, represents, or holds oneself out as a |
|
person who sells kratom products to consumers. |
|
(6) "Manufacture" has the meaning assigned by Section |
|
431.002. |
|
Sec. 445.002 [444.002]. TESTING AND LABELING [LABEL] |
|
REQUIRED. (a) Before a kratom product is sold at retail or |
|
otherwise introduced into commerce in this state, a sample |
|
representing the kratom product must be tested: |
|
(1) by a laboratory that is: |
|
(A) located in this state; and |
|
(B) accredited by an accreditation body in |
|
accordance with International Organization for Standardization |
|
ISO/IEC 17025 or a comparable or successor standard; and |
|
(2) to determine: |
|
(A) the concentration and identity of the |
|
alkaloids in the product; and |
|
(B) the presence or quantity of heavy metals, |
|
pesticides, microbial contamination, and any other substances in |
|
the product as prescribed by the executive commissioner. |
|
(b) A kratom processor shall label each kratom product with |
|
the product use directions necessary to ensure safe use of the |
|
product by a consumer, including the recommended serving size for |
|
the product. |
|
(c) [(b)] A kratom retailer may only sell a kratom product |
|
that is properly tested and labeled in accordance with this |
|
section. |
|
(d) A person commits an offense if the person sells or |
|
offers for sale a kratom product or a product marketed as containing |
|
kratom that is not tested or labeled as required by this section. |
|
(e) An offense under this section is a Class A misdemeanor. |
|
Sec. 445.003 [444.003]. ADULTERATED, CONTAMINATED, AND |
|
PROHIBITED KRATOM PRODUCTS. (a) A person commits an offense if |
|
the person manufactures, prepares, distributes, sells, or offers |
|
for sale [A kratom processor or kratom retailer may not prepare, |
|
distribute, sell, or offer to sell] a kratom product that: |
|
(1) is adulterated with a dangerous non-kratom |
|
substance affecting the quality or strength of the product to a |
|
degree that renders the product injurious to a consumer; |
|
(2) is contaminated with a poisonous or otherwise |
|
deleterious non-kratom substance, including any substance |
|
designated as a controlled substance by Chapter 481 (Texas |
|
Controlled Substances Act); |
|
(3) contains a level of 7-hydroxymitragynine in the |
|
alkaloid fraction that is greater than 0.1 [two] percent of the |
|
overall alkaloid composition of the product; [or] |
|
(4) contains any artificial or synthetic alkaloids, |
|
including artificial or synthetic 7-hydroxymitragynine and |
|
synthetically derived compounds from [a] kratom; |
|
(5) is a prepackaged beverage; or |
|
(6) is a prepackaged food other than: |
|
(A) raw or dried kratom leaves; |
|
(B) ground kratom leaves; |
|
(C) kratom leaf powder; or |
|
(D) clear capsules containing kratom leaf powder |
|
[plant]. |
|
(b) An offense under this section is a Class A misdemeanor. |
|
(c) A kratom product described by Subsection (a) is |
|
considered to be adulterated for purposes of Chapter 431. |
|
Sec. 445.004 [444.004]. OFFENSE: [FOR] DISTRIBUTION OR |
|
SALE OF KRATOM PRODUCT TO INDIVIDUAL YOUNGER THAN 21 YEARS OF AGE |
|
[MINOR]. (a) A person commits an offense if the person |
|
distributes, sells, or exposes for sale a kratom product or a |
|
product marketed as containing kratom to an individual younger than |
|
21 [18] years of age. |
|
(b) An offense under this section is a Class A [C] |
|
misdemeanor. |
|
Sec. 445.005. OFFENSE: SALE OR DELIVERY OF CERTAIN KRATOM |
|
PRODUCTS NEAR SCHOOL. (a) In this section, "school" and |
|
"premises" have the meanings assigned by Section 481.134. |
|
(b) A person commits an offense if the person sells, offers |
|
for sale, or delivers a kratom product or a product marketed as |
|
containing kratom in, on, or within 1,000 feet of the premises of a |
|
school. |
|
(c) An offense under this section is a Class A misdemeanor. |
|
Sec. 445.006. OFFENSE: FALSE LABORATORY REPORT. (a) A |
|
person commits an offense if the person, with the intent to deceive, |
|
forges, falsifies, or alters the results of a laboratory test |
|
authorized or required by this chapter. |
|
(b) An offense under this section is a felony of the third |
|
degree. |
|
Sec. 445.007. OFFENSE: SALE OF OTHER PRODUCTS PROHIBITED. |
|
(a) A person commits an offense if the person sells or offers for |
|
sale a kratom product or a product marketed as containing kratom at |
|
a location that also sells or offers for sale the following products |
|
or products marketed as the following products: |
|
(1) a consumable hemp product as defined by Section |
|
443.001; |
|
(2) a cigarette, e-cigarette, or tobacco product as |
|
defined by Section 161.081; or |
|
(3) an alcoholic beverage as defined by Section 1.04, |
|
Alcoholic Beverage Code. |
|
(b) An offense under this section is a Class A misdemeanor. |
|
Sec. 445.0071. OFFENSE: MANUFACTURE, DISTRIBUTION, OR SALE |
|
OF KRATOM PRODUCT FOR SMOKING. (a) In this section, "smoking" |
|
means burning or igniting a substance and inhaling the smoke or |
|
heating a substance and inhaling the resulting vapor or aerosol. |
|
(b) A person commits an offense if the person manufactures, |
|
distributes, sells, or offers for sale a kratom product or a product |
|
marketed as containing kratom for smoking. |
|
(c) An offense under this section is a Class A misdemeanor. |
|
Sec. 445.0072. OFFENSE: MANUFACTURE, DISTRIBUTION, OR SALE |
|
OF PILL OR TABLET CONTAINING KRATOM. (a) A person commits an |
|
offense if the person manufactures, distributes, sells, or offers |
|
for sale a pill or tablet that contains kratom or that is marketed |
|
as containing kratom. For purposes of this subsection, a capsule is |
|
not considered to be a pill or tablet. |
|
(b) An offense under this section is a Class A misdemeanor. |
|
Sec. 445.008 [444.005]. CIVIL PENALTY. (a) A person who |
|
violates this chapter is subject to a civil penalty in the amount |
|
of: |
|
(1) $2,500 [$250] for the first violation; |
|
(2) $5,000 [$500] for the second violation; and |
|
(3) $10,000 [$1,000] for each subsequent violation. |
|
(b) Each day a violation continues or occurs is a separate |
|
violation for purposes of imposing a penalty under this section. |
|
(c) [A kratom retailer is not liable for a civil penalty |
|
under this section for a violation of Section 444.002 or 444.003 if |
|
the kratom retailer proves by a preponderance of the evidence that |
|
the violation was unintentional and due to the kratom retailer's |
|
good faith reliance on the representation of another kratom |
|
processor. |
|
[(d)] The attorney general or the district or county |
|
attorney for the county or municipal attorney for the municipality |
|
in which the violation is alleged to have occurred may bring an |
|
action to recover a civil penalty under this section. |
|
Sec. 445.009 [444.006]. PENALTIES UNDER OTHER LAW. The |
|
penalties prescribed by this chapter are in addition to any other |
|
penalties prescribed by law, including penalties prescribed by |
|
Chapters 431 and 481. |
|
Sec. 445.010 [444.007]. RULES. The executive commissioner |
|
may adopt rules consistent with this chapter as necessary to ensure |
|
the safe consumption and distribution of kratom and kratom |
|
products. |
|
SECTION 2. Section 481.002, Health and Safety Code, is |
|
amended by adding Subdivision (56) to read as follows: |
|
(56) "Kratom" means any part of the leaf of the plant |
|
of the species Mitragyna speciosa. |
|
SECTION 3. Section 481.102, Health and Safety Code, is |
|
amended to read as follows: |
|
Sec. 481.102. PENALTY GROUP 1. Penalty Group 1 consists of: |
|
(1) the following opiates, including their isomers, |
|
esters, ethers, salts, and salts of isomers, esters, and ethers, |
|
unless specifically excepted, if the existence of these isomers, |
|
esters, ethers, and salts is possible within the specific chemical |
|
designation: |
|
Allylprodine; |
|
Alphacetylmethadol; |
|
Benzethidine; |
|
Betaprodine; |
|
Clonitazene; |
|
Diampromide; |
|
Diethylthiambutene; |
|
Difenoxin not listed in Penalty Group 3 or 4; |
|
Dimenoxadol; |
|
Dimethylthiambutene; |
|
Dioxaphetyl butyrate; |
|
Dipipanone; |
|
Ethylmethylthiambutene; |
|
Etodesnitazene; |
|
Etonitazene; |
|
Etoxeridine; |
|
Furethidine; |
|
Hydroxypethidine; |
|
Ketobemidone; |
|
Levophenacylmorphan; |
|
Meprodine; |
|
Methadol; |
|
Moramide; |
|
Morpheridine; |
|
Noracymethadol; |
|
Norlevorphanol; |
|
Normethadone; |
|
Norpipanone; |
|
N-pyrrolidino etonitazene; |
|
Phenadoxone; |
|
Phenampromide; |
|
Phenomorphan; |
|
Phenoperidine; |
|
Piritramide; |
|
Proheptazine; |
|
Properidine; |
|
Propiram; |
|
Protonitazene; |
|
Tilidine; and |
|
Trimeperidine; |
|
(2) the following opium derivatives, their salts, |
|
isomers, and salts of isomers, unless specifically excepted, if the |
|
existence of these salts, isomers, and salts of isomers is possible |
|
within the specific chemical designation: |
|
Acetorphine; |
|
Acetyldihydrocodeine; |
|
Benzylmorphine; |
|
Codeine methylbromide; |
|
Codeine-N-Oxide; |
|
Cyprenorphine; |
|
Desomorphine; |
|
Dihydromorphine; |
|
Drotebanol; |
|
Etorphine, except hydrochloride salt; |
|
Heroin; |
|
Hydromorphinol; |
|
Methyldesorphine; |
|
Methyldihydromorphine; |
|
Monoacetylmorphine; |
|
Morphine methylbromide; |
|
Morphine methylsulfonate; |
|
Morphine-N-Oxide; |
|
Myrophine; |
|
Nicocodeine; |
|
Nicomorphine; |
|
Normorphine; |
|
Pholcodine; and |
|
Thebacon; |
|
(3) the following substances, however produced, |
|
except those narcotic drugs listed in another group: |
|
(A) Opium and opiate not listed in Penalty Group |
|
3 or 4, and a salt, compound, derivative, or preparation of opium or |
|
opiate, other than thebaine derived butorphanol, nalmefene and its |
|
salts, naloxone and its salts, and naltrexone and its salts, but |
|
including: |
|
Codeine not listed in Penalty Group 3 or 4; |
|
Dihydroetorphine; |
|
Ethylmorphine not listed in Penalty Group 3 |
|
or 4; |
|
Granulated opium; |
|
Hydrocodone not listed in Penalty Group 3; |
|
Hydromorphone; |
|
Metopon; |
|
Morphine not listed in Penalty Group 3; |
|
Opium extracts; |
|
Opium fluid extracts; |
|
Oripavine; |
|
Oxycodone; |
|
Oxymorphone; |
|
Powdered opium; |
|
Raw opium; |
|
Thebaine; and |
|
Tincture of opium; |
|
(B) a salt, compound, isomer, derivative, or |
|
preparation of a substance that is chemically equivalent or |
|
identical to a substance described by Paragraph (A), other than the |
|
isoquinoline alkaloids of opium; |
|
(C) Opium poppy and poppy straw; |
|
(D) Cocaine, including: |
|
(i) its salts, its optical, position, and |
|
geometric isomers, and the salts of those isomers; |
|
(ii) coca leaves and a salt, compound, |
|
derivative, or preparation of coca leaves; and |
|
(iii) a salt, compound, derivative, or |
|
preparation of a salt, compound, or derivative that is chemically |
|
equivalent or identical to a substance described by Subparagraph |
|
(i) or (ii), other than decocainized coca leaves or extractions of |
|
coca leaves that do not contain cocaine or ecgonine; [and] |
|
(E) concentrate of poppy straw, meaning the crude |
|
extract of poppy straw in liquid, solid, or powder form that |
|
contains the phenanthrine alkaloids of the opium poppy; |
|
(F) kratom alkaloids, other than within kratom, |
|
as well as artificial equivalents of the substances naturally |
|
created in a plant of the species Mitragyna speciosa, as well as |
|
synthetic equivalents of the substances naturally created in a |
|
plant of the species Mitragyna speciosa, including: |
|
(i) mitragynine; |
|
(ii) 7-hydroxymitragynine; |
|
(iii) corynantheidine; |
|
(iv) speciofoline; |
|
(v) speciociliatine; |
|
(vi) speciogynine; |
|
(vii) paynantheine; |
|
(viii) mitraciliatine; and |
|
(ix) corynoxine; |
|
(G) any salt, isomer, salt of isomer, compound, |
|
derivative, extract, or preparation of a substance described by |
|
Paragraph (F) with similar pharmacological activity, as well as any |
|
other analogue of a substance described by Paragraph (F) intended |
|
to interact with human opioid receptors; and |
|
(H) Tianeptine and any salt, isomer, salt of |
|
isomer, compound, derivative, extract, or preparation of |
|
tianeptine with similar pharmacological activity, as well as any |
|
other analogue of tianeptine intended to interact with human opioid |
|
receptors; |
|
(4) the following opiates, including their isomers, |
|
esters, ethers, salts, and salts of isomers, if the existence of |
|
these isomers, esters, ethers, and salts is possible within the |
|
specific chemical designation: |
|
Alphaprodine; |
|
Anileridine; |
|
Bezitramide; |
|
Dihydrocodeine not listed in Penalty Group 3 or 4; |
|
Diphenoxylate not listed in Penalty Group 3 or 4; |
|
Isomethadone; |
|
Levomethorphan; |
|
Levorphanol; |
|
Metazocine; |
|
Methadone; |
|
Methadone-Intermediate, 4-cyano-2-dimethylamino- |
|
4, 4-diphenyl butane; |
|
Moramide-Intermediate, 2-methyl-3-morpholino-1, |
|
1-diphenyl-propane-carboxylic acid; |
|
PEPAP (1-(2-phenethyl)-4-phenyl-4- |
|
acetoxypiperidine); |
|
Pethidine (Meperidine); |
|
Pethidine-Intermediate-A, 4-cyano-1-methyl-4- |
|
phenylpiperidine; |
|
Pethidine-Intermediate-B, ethyl-4- |
|
phenylpiperidine-4 carboxylate; |
|
Pethidine-Intermediate-C, 1-methyl-4- |
|
phenylpiperidine-4-carboxylic acid; |
|
Phenazocine; |
|
Piminodine; |
|
Racemethorphan; and |
|
Racemorphan; |
|
(5) Flunitrazepam (trade or other name: Rohypnol); |
|
(6) Methamphetamine, including its salts, optical |
|
isomers, and salts of optical isomers; |
|
(7) Phenylacetone and methylamine, if possessed |
|
together with intent to manufacture methamphetamine; |
|
(8) Phencyclidine, including its salts; |
|
(9) Gamma hydroxybutyric acid (some trade or other |
|
names: gamma hydroxybutyrate, GHB), including its salts; |
|
(10) Ketamine; |
|
(11) Phenazepam; |
|
(12) U-47700; |
|
(13) AH-7921; |
|
(14) ADB-FUBINACA; |
|
(15) AMB-FUBINACA; and |
|
(16) MDMB-CHMICA. |
|
SECTION 4. Section 481.103(a), Health and Safety Code, is |
|
amended to read as follows: |
|
(a) Penalty Group 2 consists of: |
|
(1) any quantity of the following hallucinogenic |
|
substances, their salts, isomers, and salts of isomers, unless |
|
specifically excepted, if the existence of these salts, isomers, |
|
and salts of isomers is possible within the specific chemical |
|
designation: |
|
5-(2-aminopropyl)benzofuran (5-APB); |
|
6-(2-aminopropyl)benzofuran (6-APB); |
|
5-(2-aminopropyl)-2,3-dihydrobenzofuran |
|
(5-APDB); |
|
6-(2-aminopropyl)-2,3-dihydrobenzofuran |
|
(6-APDB); |
|
5-(2-aminopropyl)indole (5-IT,5-API); |
|
6-(2-aminopropyl)indole (6-IT,6-API); |
|
1-(benzofuran-5-yl)-N-methylpropan-2-amine |
|
(5-MAPB); |
|
1-(benzofuran-6-yl)-N-methylpropan-2-amine |
|
(6-MAPB); |
|
Benzothiophenylcyclohexylpiperidine (BTCP); |
|
8-bromo-alpha-methyl-benzo[1,2-b:4,5-b']difuran- |
|
4-ethanamine (trade or other name: Bromo-DragonFLY); |
|
Desoxypipradrol (2-benzhydrylpiperidine); |
|
2, 5-dimethoxyamphetamine (some trade or other |
|
names: 2, 5-dimethoxy-alpha-methylphenethylamine; 2, 5-DMA); |
|
Diphenylprolinol (diphenyl(pyrrolidin-2-yl) |
|
methanol, D2PM); |
|
Dronabinol (synthetic) in sesame oil and |
|
encapsulated in a soft gelatin capsule in a U.S. Food and Drug |
|
Administration approved drug product (some trade or other names for |
|
Dronabinol: (a6aR-trans)-6a,7,8,10a-tetrahydro- 6,6, 9- |
|
trimethyl-3-pentyl-6H- dibenzo [b,d]pyran-1-ol or (-)-delta-9- |
|
(trans)- tetrahydrocannabinol); |
|
Ethylamine Analog of Phencyclidine (some trade or |
|
other names: N-ethyl-1-phenylcyclohexylamine, (1- |
|
phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine, |
|
cyclohexamine, PCE); |
|
2-ethylamino-2-(3-methoxyphenyl)cyclohexanone |
|
(trade or other name: methoxetamine); |
|
Ibogaine (some trade or other names: 7-Ethyl-6, |
|
6, beta 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5H- |
|
pyrido [1', 2':1, 2] azepino [5, 4-b] indole; tabernanthe iboga.); |
|
5-iodo-2-aminoindane (5-IAI); |
|
Mescaline; |
|
5-methoxy-3, 4-methylenedioxy amphetamine; |
|
4-methoxyamphetamine (some trade or other |
|
names: 4-methoxy-alpha-methylphenethylamine; |
|
paramethoxyamphetamine; PMA); |
|
4-methoxymethamphetamine (PMMA); |
|
2-(2-methoxyphenyl)-2-(methylamino)cyclohexanone |
|
(some trade and other names: 2-MeO-ketamine; methoxyketamine); |
|
1-methyl- 4-phenyl-4-propionoxypiperidine (MPPP, |
|
PPMP); |
|
4-methyl-2, 5-dimethoxyamphetamine (some trade |
|
and other names: 4-methyl-2, 5-dimethoxy-alpha- |
|
methylphenethylamine; "DOM"; "STP"); |
|
3,4-methylenedioxy methamphetamine (MDMA, MDM); |
|
3,4-methylenedioxy amphetamine; |
|
3,4-methylenedioxy N-ethylamphetamine (Also |
|
known as N-ethyl MDA); |
|
5,6-methylenedioxy-2-aminoindane (MDAI); |
|
Nabilone (Another name for nabilone: (+)-trans- |
|
3-(1,1-dimethylheptyl)- 6,6a, 7,8,10,10a-hexahydro-1-hydroxy- 6, |
|
6-dimethyl-9H-dibenzo[b,d] pyran-9-one; |
|
N-benzylpiperazine (some trade or other |
|
names: BZP; 1-benzylpiperazine); |
|
N-ethyl-3-piperidyl benzilate; |
|
N-hydroxy-3,4-methylenedioxyamphetamine (Also |
|
known as N-hydroxy MDA); |
|
4-methylaminorex; |
|
N-methyl-3-piperidyl benzilate; |
|
Parahexyl (some trade or other names: 3-Hexyl-1- |
|
hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo [b, d] |
|
pyran; Synhexyl); |
|
1-Phenylcyclohexylamine; |
|
1-Piperidinocyclohexanecarbonitrile (PCC); |
|
Pyrrolidine Analog of Phencyclidine (some trade |
|
or other names: 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP); |
|
Tetrahydrocannabinols, other than marihuana, and |
|
synthetic equivalents of the substances contained in the plant, or |
|
in the resinous extractives of Cannabis, or synthetic substances, |
|
derivatives, and their metabolites, isomers, acids, salts, and |
|
salts of isomers with similar chemical structure and |
|
pharmacological activity, including [such as]: |
|
delta-1 cis or trans tetrahydrocannabinol, |
|
and their optical isomers; |
|
delta-6 cis or trans tetrahydrocannabinol, |
|
and their optical isomers; |
|
delta-3, 4 cis or trans |
|
tetrahydrocannabinol, and its optical isomers; |
|
delta-5, cis or trans tetrahydrocannabinol, |
|
and their optical isomers; |
|
delta-6a, cis or trans tetrahydrocannabinol, |
|
and their optical isomers; |
|
delta-7, cis or trans tetrahydrocannabinol, |
|
and their optical isomers; |
|
delta-7a, cis or trans tetrahydrocannabinol, |
|
and their optical isomers; |
|
delta-8, cis or trans tetrahydrocannabinol, |
|
and their optical isomers; |
|
delta-10, cis or trans tetrahydrocannabinol, |
|
and their optical isomers; |
|
delta-10a, cis or trans |
|
tetrahydrocannabinol, and their optical isomers; |
|
delta-11, cis or trans tetrahydrocannabinol, |
|
and their optical isomers; |
|
delta-11-Hydroxy-tetrahydrocannabinol; |
|
exo-tetrahydrocannabinol; |
|
tetrahydrocannabivarins, including delta-8 |
|
tetrahydrocannabivarin; |
|
11-hydroxy-tetrahydrocannabinol; |
|
3-hydroxy-tetrahydrocannabinol; |
|
7-hydroxy-tetrahydrocannabinol; |
|
hexahydrocannabiphorol-o-ester; |
|
hydrogenated forms of tetrahydrocannabinol, |
|
including hexahydrocannabinol, hexahydrocannabiphorol, and |
|
hexahydrocannabihexol; |
|
hydrogenated forms of hexahydrocannabinol, |
|
including 8-hydroxyhexahydrocannabinol and |
|
10-hydroxyhexahydrocannabinol; |
|
ester forms of tetrahydrocannabinol, |
|
including delta-8 THC-O-acetate, delta-9 THC-O-acetate, and |
|
hexahydrocannabinol-O-acetate; |
|
tetrahydrocannabinols with alkyl chain of |
|
four or more carbon atoms, including tetrahydrocannabiphorols, |
|
tetrahydrocannabioctyls, tetrahydrocannabihexols, |
|
tetrahydrocannabidiol, and tetrahydrocannabutols; |
|
tetrahydrocannabinol acetate; |
|
tetrahydrocannabinol methyl ester; or |
|
compounds of these structures, regardless of |
|
numerical designation of atomic positions, since nomenclature of |
|
these substances is not internationally standardized; |
|
Thiophene Analog of Phencyclidine (some trade or |
|
other names: 1-[1-(2-thienyl) cyclohexyl] piperidine; 2-Thienyl |
|
Analog of Phencyclidine; TPCP, TCP); |
|
1-pyrrolidine (some trade or other name: TCPy); |
|
1-(3-trifluoromethylphenyl)piperazine (trade or |
|
other name: TFMPP); and |
|
3,4,5-trimethoxy amphetamine; |
|
(2) Phenylacetone (some trade or other |
|
names: Phenyl-2-propanone; P2P, Benzymethyl ketone, methyl benzyl |
|
ketone); |
|
(3) unless specifically excepted or unless listed in |
|
another Penalty Group, a material, compound, mixture, or |
|
preparation that contains any quantity of the following substances |
|
having a potential for abuse associated with a depressant or |
|
stimulant effect on the central nervous system: |
|
Aminorex (some trade or other |
|
names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; 4,5-dihydro-5- |
|
phenyl-2-oxazolamine); |
|
Amphetamine, its salts, optical isomers, and |
|
salts of optical isomers; |
|
Cathinone (some trade or other names: 2-amino-1- |
|
phenyl-1-propanone, alpha-aminopropiophenone, 2- |
|
aminopropiophenone); |
|
Etaqualone and its salts; |
|
Etorphine Hydrochloride; |
|
Fenethylline and its salts; |
|
Lisdexamfetamine, including its salts, isomers, |
|
and salts of isomers; |
|
Mecloqualone and its salts; |
|
Methaqualone and its salts; |
|
Methcathinone (some trade or other names: 2- |
|
methylamino-propiophenone; alpha-(methylamino)propriophenone; |
|
2-(methylamino)-1-phenylpropan-1-one; alpha-N- |
|
methylaminopropriophenone; monomethylpropion; ephedrone, N- |
|
methylcathinone; methylcathinone; AL-464; AL-422; AL-463; and UR |
|
1431); |
|
N-Ethylamphetamine, its salts, optical isomers, |
|
and salts of optical isomers; and |
|
N,N-dimethylamphetamine (some trade or other |
|
names: N,N,alpha-trimethylbenzeneethanamine; |
|
N,N,alpha-trimethylphenethylamine), its salts, optical isomers, |
|
and salts of optical isomers; |
|
(4) any compound structurally derived from |
|
2-aminopropanal by substitution at the 1-position with any |
|
monocyclic or fused-polycyclic ring system, including: |
|
(A) compounds further modified by: |
|
(i) substitution in the ring system to any |
|
extent (including alkyl, alkoxy, alkylenedioxy, haloalkyl, or |
|
halide substituents), whether or not further substituted in the |
|
ring system by other substituents; |
|
(ii) substitution at the 3-position with an |
|
alkyl substituent; or |
|
(iii) substitution at the 2-amino nitrogen |
|
atom with alkyl, benzyl, dialkyl, or methoxybenzyl groups, or |
|
inclusion of the 2-amino nitrogen atom in a cyclic structure; and |
|
(B) by example, compounds such as: |
|
4-Methylmethcathinone (Also known as |
|
Mephedrone); |
|
3,4-Dimethylmethcathinone (Also known as |
|
3,4-DMMC); |
|
3-Fluoromethcathinone (Also known as 3-FMC); |
|
4-Fluoromethcathinone (Also known as |
|
Flephedrone); |
|
3,4-Methylenedioxy-N-methylcathinone (Also |
|
known as Methylone); |
|
3,4-Methylenedioxypyrovalerone (Also known |
|
as MDPV); |
|
alpha-Pyrrolidinopentiophenone (Also known |
|
as alpha-PVP); |
|
Naphthylpyrovalerone (Also known as |
|
Naphyrone); |
|
alpha-Methylamino-valerophenone (Also known |
|
as Pentedrone); |
|
beta-Keto-N-methylbenzodioxolylpropylamine |
|
(Also known as Butylone); |
|
beta-Keto-N-methylbenzodioxolylpentanamine |
|
(Also known as Pentylone); |
|
beta-Keto-Ethylbenzodioxolylbutanamine |
|
(Also known as Eutylone); and |
|
3,4-methylenedioxy-N-ethylcathinone (Also |
|
known as Ethylone); |
|
(5) any compound structurally derived from tryptamine |
|
(3-(2-aminoethyl)indole) or a ring-hydroxy tryptamine: |
|
(A) by modification in any of the following ways: |
|
(i) by substitution at the amine nitrogen |
|
atom of the sidechain to any extent with alkyl or alkenyl groups or |
|
by inclusion of the amine nitrogen atom of the side chain (and no |
|
other atoms of the side chain) in a cyclic structure; |
|
(ii) by substitution at the carbon atom |
|
adjacent to the nitrogen atom of the side chain (alpha-position) |
|
with an alkyl or alkenyl group; |
|
(iii) by substitution in the 6-membered |
|
ring to any extent with alkyl, alkoxy, haloalkyl, thioaklyl, |
|
alkylenedioxy, or halide substituents; or |
|
(iv) by substitution at the 2-position of |
|
the tryptamine ring system with an alkyl substituent; and |
|
(B) including: |
|
(i) ethers and esters of the controlled |
|
substances listed in this subdivision; and |
|
(ii) by example, compounds such as: |
|
alpha-ethyltryptamine; |
|
alpha-methyltryptamine; |
|
Bufotenine (some trade and other names: |
|
3-(beta-Dimethylaminoethyl)-5-hydroxyindole; |
|
3-(2-dimethylaminoethyl)- 5- indolol; N, N-dimethylserotonin; |
|
5-hydroxy-N, N- dimethyltryptamine; mappine); |
|
Diethyltryptamine (some trade and |
|
other names: N, N-Diethyltryptamine, DET); |
|
Dimethyltryptamine (trade or other |
|
name: DMT); |
|
5-methoxy-N, N-diisopropyltryptamine |
|
(5-MeO-DiPT); |
|
O-Acetylpsilocin (Trade or other name: |
|
4-Aco-DMT); |
|
Psilocin; and |
|
Psilocybin; |
|
(6) 2,5-Dimethoxyphenethylamine and any compound |
|
structurally derived from 2,5-Dimethoxyphenethylamine by |
|
substitution at the 4-position of the phenyl ring to any extent |
|
(including alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide |
|
substituents), including, by example, compounds such as: |
|
4-Bromo-2,5-dimethoxyphenethylamine (trade or |
|
other name: 2C-B); |
|
4-Chloro-2,5-dimethoxyphenethylamine (trade or |
|
other name: 2C-C); |
|
2,5-Dimethoxy-4-methylphenethylamine (trade or |
|
other name: 2C-D); |
|
4-Ethyl-2,5-dimethoxyphenethylamine (trade or |
|
other name: 2C-E); |
|
4-Iodo-2,5-dimethoxyphenethylamine (trade or |
|
other name: 2C-I); |
|
2,5-Dimethoxy-4-nitrophenethylamine (trade or |
|
other name: 2C-N); |
|
2,5-Dimethoxy-4-(n)-propylphenethylamine (trade |
|
or other name: 2C-P); |
|
4-Ethylthio-2,5-dimethoxyphenethylamine (trade |
|
or other name: 2C-T-2); |
|
4-Isopropylthio-2,5-dimethoxyphenethylamine |
|
(trade or other name: 2C-T-4); and |
|
2,5-Dimethoxy-4-(n)-propylthiophenethylamine |
|
(trade or other name: 2C-T-7); [and] |
|
(7) 2,5-Dimethoxyamphetamine and any compound |
|
structurally derived from 2,5-Dimethoxyamphetamine by substitution |
|
at the 4-position of the phenyl ring to any extent (including alkyl, |
|
alkoxy, alkylenedioxy, haloalkyl, or halide substituents), |
|
including, by example, compounds such as: |
|
4-Ethylthio-2,5-dimethoxyamphetamine (trade or |
|
other name: Aleph-2); |
|
4-Isopropylthio-2,5-dimethoxyamphetamine (trade |
|
or other name: Aleph-4); |
|
4-Bromo-2,5-dimethoxyamphetamine (trade or other |
|
name: DOB); |
|
4-Chloro-2,5-dimethoxyamphetamine (trade or |
|
other name: DOC); |
|
2,5-Dimethoxy-4-ethylamphetamine (trade or other |
|
name: DOET); |
|
4-Iodo-2,5-dimethoxyamphetamine (trade or other |
|
name: DOI); |
|
2,5-Dimethoxy-4-methylamphetamine (trade or |
|
other name: DOM); |
|
2,5-Dimethoxy-4-nitroamphetamine (trade or other |
|
name: DON); |
|
4-Isopropyl-2,5-dimethoxyamphetamine (trade or |
|
other name: DOIP); and |
|
2,5-Dimethoxy-4-(n)-propylamphetamine (trade or |
|
other name: DOPR); and |
|
(8) any quantity of the following hallucinogenic |
|
substances, their salts, isomers, salts of isomers, ethers, and |
|
esters unless specifically excepted, if the existence of these |
|
salts, isomers, salts of isomers, ethers, and esters is possible: |
|
Ibotenic acid; and |
|
Muscimol. |
|
SECTION 5. The changes in law made by this Act apply only to |
|
an offense committed on or after the effective date of this Act. An |
|
offense committed before the effective date of this Act is governed |
|
by the law in effect on the date the offense was committed, and the |
|
former law is continued in effect for that purpose. For purposes of |
|
this section, an offense was committed before the effective date of |
|
this Act if any element of the offense occurred before that date. |
|
SECTION 6. To the extent of any conflict, this Act prevails |
|
over another Act of the 89th Legislature, Regular Session, 2025, |
|
relating to nonsubstantive additions to and corrections in enacted |
|
codes. |
|
SECTION 7. This Act takes effect September 1, 2025. |